Shandong Xinhua Pharmaceutical Co Ltd (000756) - Net Assets
Based on the latest financial reports, Shandong Xinhua Pharmaceutical Co Ltd (000756) has net assets worth CN¥5.36 Billion CNY (≈ $785.07 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥9.24 Billion ≈ $1.35 Billion USD) and total liabilities (CN¥3.87 Billion ≈ $566.69 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Shandong Xinhua Pharmaceutical Co Ltd (000756) strategic asset index to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥5.36 Billion |
| % of Total Assets | 58.08% |
| Annual Growth Rate | 11.34% |
| 5-Year Change | 53.85% |
| 10-Year Change | N/A |
| Growth Volatility | 5.77 |
Shandong Xinhua Pharmaceutical Co Ltd - Net Assets Trend (2015–2024)
This chart illustrates how Shandong Xinhua Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Shandong Xinhua Pharmaceutical Co Ltd market capitalisation.
Annual Net Assets for Shandong Xinhua Pharmaceutical Co Ltd (2015–2024)
The table below shows the annual net assets of Shandong Xinhua Pharmaceutical Co Ltd from 2015 to 2024. Also explore 000756 net assets growth trend to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥5.22 Billion ≈ $763.48 Million |
+9.25% |
| 2023-12-31 | CN¥4.78 Billion ≈ $698.84 Million |
+9.79% |
| 2022-12-31 | CN¥4.35 Billion ≈ $636.53 Million |
+19.14% |
| 2021-12-31 | CN¥3.65 Billion ≈ $534.28 Million |
+7.66% |
| 2020-12-31 | CN¥3.39 Billion ≈ $496.25 Million |
+9.03% |
| 2019-12-31 | CN¥3.11 Billion ≈ $455.17 Million |
+11.23% |
| 2018-12-31 | CN¥2.80 Billion ≈ $409.22 Million |
+8.42% |
| 2017-12-31 | CN¥2.58 Billion ≈ $377.46 Million |
+24.05% |
| 2016-12-31 | CN¥2.08 Billion ≈ $304.27 Million |
+4.80% |
| 2015-12-31 | CN¥1.98 Billion ≈ $290.33 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Shandong Xinhua Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 233.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥2.55 Billion | 51.09% |
| Other Components | CN¥2.44 Billion | 48.91% |
| Total Equity | CN¥4.99 Billion | 100.00% |
Shandong Xinhua Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Shandong Xinhua Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CHERVON HOLDINGS LTD
F:AZ9
|
$965.89 Million |
|
Tyntek Corp
TW:2426
|
$966.06 Million |
|
Shandong Bohui Paper Industry Co Ltd
SHG:600966
|
$966.37 Million |
|
FAWER Automotive Parts Ltd Co
SHE:000030
|
$966.43 Million |
|
Guangxi Wuzhou Communications Co Ltd
SHG:600368
|
$965.73 Million |
|
ArcherMind Technology Nanjing Co Ltd
SHE:300598
|
$965.56 Million |
|
Wereldhave NV
AS:WHA
|
$965.06 Million |
|
Metalurgica Gerdau S.A
SA:GOAU3
|
$964.75 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shandong Xinhua Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 4,553,103,870 to 4,991,588,525, a change of 438,484,655 (9.6%).
- Net income of 470,023,746 contributed positively to equity growth.
- Dividend payments of 225,847,089 reduced retained earnings.
- Other factors increased equity by 194,307,998.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥470.02 Million | +9.42% |
| Dividends Paid | CN¥225.85 Million | -4.52% |
| Other Changes | CN¥194.31 Million | +3.89% |
| Total Change | CN¥- | 9.63% |
Book Value vs Market Value Analysis
This analysis compares Shandong Xinhua Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.82x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 3.34x to 1.82x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | CN¥3.99 | CN¥13.34 | x |
| 2018-12-31 | CN¥4.32 | CN¥13.34 | x |
| 2019-12-31 | CN¥4.77 | CN¥13.34 | x |
| 2020-12-31 | CN¥5.18 | CN¥13.34 | x |
| 2021-12-31 | CN¥5.53 | CN¥13.34 | x |
| 2022-12-31 | CN¥6.16 | CN¥13.34 | x |
| 2023-12-31 | CN¥6.75 | CN¥13.34 | x |
| 2024-12-31 | CN¥7.31 | CN¥13.34 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shandong Xinhua Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 9.42%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.55%
- • Asset Turnover: 0.94x
- • Equity Multiplier: 1.81x
- Recent ROE (9.42%) is above the historical average (8.89%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 4.41% | 2.31% | 0.80x | 2.38x | CN¥-105.36 Million |
| 2016 | 6.15% | 3.05% | 0.85x | 2.38x | CN¥-76.57 Million |
| 2017 | 8.45% | 4.64% | 0.86x | 2.13x | CN¥-38.41 Million |
| 2018 | 9.33% | 4.82% | 0.88x | 2.20x | CN¥-17.89 Million |
| 2019 | 10.10% | 5.35% | 0.87x | 2.17x | CN¥3.06 Million |
| 2020 | 10.08% | 5.41% | 0.85x | 2.20x | CN¥2.48 Million |
| 2021 | 10.05% | 5.31% | 0.89x | 2.11x | CN¥1.75 Million |
| 2022 | 9.96% | 5.48% | 0.91x | 2.00x | CN¥-1.45 Million |
| 2023 | 10.90% | 6.13% | 0.98x | 1.82x | CN¥41.20 Million |
| 2024 | 9.42% | 5.55% | 0.94x | 1.81x | CN¥-29.14 Million |
Industry Comparison
This section compares Shandong Xinhua Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $8,448,219,723
- Average return on equity (ROE) among peers: 10.70%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shandong Xinhua Pharmaceutical Co Ltd (000756) | CN¥5.36 Billion | 4.41% | 0.72x | $965.83 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $2.14 Billion | 22.15% | 4.96x | $585.22 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.15 Billion | 3.98% | 1.16x | $407.31 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $897.61 Million | 10.79% | 0.14x | $4.27 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $14.94 Billion | 12.78% | 0.66x | $2.26 Billion |
| Wedge Industrial Co Ltd (000534) | $552.92 Million | 0.39% | 0.01x | $1.78 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $38.10 Billion | 10.98% | 0.30x | $13.33 Billion |
| Hainan Haiyao Co Ltd (000566) | $5.63 Billion | 2.92% | 0.71x | $875.19 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $141.91 Million | 11.01% | 0.32x | $311.17 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $2.05 Billion | 23.18% | 1.96x | $973.03 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $18.87 Billion | 8.83% | 0.08x | $3.07 Billion |
About Shandong Xinhua Pharmaceutical Co Ltd
Shandong Xinhua Pharmaceutical Company Limited develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally. It offers antipyretic and analgesic, cardiovascular and cerebrovascular, anti-infective, and central nervous drugs under the Xinhua brand; and contract manufacturing services for act… Read more